Intralymphatic immunotherapy
Authors:
- 1 March 2024
- journal article
- editorial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 132 (3) , 255-256
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trialAnnals of Allergy, Asthma & Immunology, 2023
- Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double‐blind placebo‐controlled clinical trialClinical & Experimental Allergy, 2023
- Strengthening the case for intralymphatic immunotherapyCurrent Opinion in Allergy and Clinical Immunology, 2022
- Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta‐analysisClinical and Translational Allergy, 2021
- High‐dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increaseAllergy, 2021
- Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trialRespiratory Research, 2021
- Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trialJournal of Allergy and Clinical Immunology, 2021
- Intralymphatic immunotherapy for mountain cedar pollinosisAnnals of Allergy, Asthma & Immunology, 2020